102460 — Reyon Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSucker Stock

Market Cap
KR₩253bn
Enterprise Value
KR₩460bn
Revenue
KR₩151bn

Annual income statement for Reyon Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	131,558	130,034	142,801	154,039	151,071
Cost of Revenue
Gross Profit	74,262	72,585	79,438	81,728	78,899
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	125,913	125,893	139,062	144,406	147,038
Operating Profit	5,645	4,141	3,739	9,633	4,034
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	6,557	4,368	5,845	6,894	4,032
Provision for Income Taxes
Net Income After Taxes	4,944	3,844	5,537	7,434	3,583
Minority Interest
Net Income Before Extraordinary Items
Net Income	4,946	3,844	5,537	7,434	3,583
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	4,946	3,844	5,412	7,359	3,583
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	331	221	313	402	195
Dividends per Share